Price concessions hit fourth consecutive record high
Price concessions in England have reached a record high for the fourth month running, adding to the financial strain already bearing down on community pharmacy. The Centre for Pharmacy Education (CPE) has called for a fundamental rethink of how drugs are reimbursed — a sign that those closest to the problem no longer believe incremental fixes will work.
What happened
The latest concession figures from NHS England show that price concessions have broken records again, continuing a streak that now stretches across four consecutive months. Price concessions are granted when the Drug Tariff reimbursement price for a medicine falls so far below the actual market cost that pharmacies cannot source it without making a loss. When a concession is granted, NHS England temporarily raises the reimbursement price to reflect real-world costs.
The fact that this is happening month after month, at escalating levels, points to something more than a short-term supply blip. Drug prices are rising faster than the Drug Tariff is keeping pace with, leaving pharmacy contractors caught between what they pay suppliers and what the NHS will reimburse them.
One MP reportedly described the situation as the country being "addicted to low-cost drugs" — a phrase that captures something real about how NHS drug pricing policy has developed over decades. The push for generic medicines at the lowest possible price has delivered savings for the NHS for years, but the current concession crisis suggests that model is under serious strain.
CPE's response was direct. The organisation said there must be "a fundamental review of the current reimbursement model" — language that goes well beyond asking for a temporary uplift or a one-off adjustment.
Why it matters
For anyone working in or about to enter community pharmacy, this matters on several levels.
First, the financial one. Community pharmacy in England is already operating under significant funding pressure. The sector has faced years of real-terms funding cuts, and contractor margins have been squeezed repeatedly. Price concessions, when they work as intended, should protect pharmacies from making a loss on dispensing. But when concessions are hitting records every single month, it suggests the underlying Drug Tariff pricing is systemically out of step with the actual cost of medicines — not occasionally, not in isolated cases, but routinely.
For pharmacy owners and superintendents, that creates cash flow problems. A concession is retrospective — pharmacies dispense the medicine, pay the supplier's current price, and then receive a reimbursement that may or may not fully cover it. When concessions are widespread, the gap between outlay and reimbursement can become unmanageable.
For pre-registration trainee pharmacists working in community pharmacy right now, you'll be seeing this play out in practice. The conversations about stock availability, the calls to wholesalers, the decisions about whether to source from a secondary supplier at higher cost — these are all connected to what the concession data is describing.
Second, the policy level. CPE calling for a fundamental review of the reimbursement model is significant. This isn't a routine lobbying statement. It signals that the body representing pharmacy contractors believes the current system isn't working and can't be patched. A fundamental review would mean looking at how the Drug Tariff is structured, how Category M pricing (which covers most generic medicines) is calculated, and how quickly the system responds when market prices shift.
That kind of review, if it happens, would reshape how community pharmacy is funded. It could affect dispensing fees, category pricing, and the overall financial viability of contractor models. As someone entering the profession at this point, understanding the mechanics of pharmacy funding isn't just background knowledge — it's directly relevant to the environment you'll be working in.
Third, the supply angle. When medicines repeatedly require concessions, it often reflects underlying supply chain issues — manufacturing shortages, raw material costs, currency effects on imported generics, or distribution bottlenecks. Some of these are global. Others are specific to how NHS procurement and tendering works in England.
For patients, the consequence is sometimes delayed dispensing, partial supplies, or the need to source from a different pharmacy. As a pharmacist — and soon as a registered one — you'll be the person handling those conversations, explaining why a medicine that was available last month isn't today, and finding clinically appropriate alternatives when necessary.
GPhC exam relevance
The CRA doesn't test current affairs directly, but this situation touches on several areas that do appear in the assessment.
Medicines supply and shortage management comes up in clinical and practice questions. Knowing what a price concession is, why it gets issued, and what it means for dispensing decisions is practical pharmacy knowledge. If a concession has been granted and a patient brings in a prescription, you need to understand what you can dispense, whether a therapeutic substitute requires a prescriber's authorisation, and how to document any changes properly.
The CRA also covers professional judgement in situations where standard processes don't apply — and medicines supply shortages are exactly that kind of situation. There's no algorithmic answer to "we can't source this medicine and the patient needs it today". You weigh clinical urgency, available alternatives, what the prescriber needs to know, and what the patient has been told. Those judgements come up in exam scenarios.
At a broader level, understanding how the NHS funds pharmacy — Drug Tariff, reimbursement categories, dispensing fees — is part of the professional knowledge a pharmacist is expected to hold. The GPhC's proficiency standards include understanding the context in which pharmacy operates. The current funding crisis is part of that context.
If you haven't already looked at how the Drug Tariff works — Category M, Category A, Category H, how concessions fit into this — now is a reasonable time to do it. It's the kind of background that makes practice questions about dispensing decisions and supply shortages easier to reason through, because you understand the system rather than just the symptoms.
What's next
Watch for CPE's formal position on reimbursement reform. If the organisation does pursue a fundamental review, it will go to NHS England and the Department of Health and Social Care. The outcome — whether that's a reformed Category M pricing mechanism, a faster concession process, or something more structural — will affect every community pharmacy in England.
Watch the monthly concession lists from NHS England. If you're on placement in community pharmacy, check which medicines are currently under concession. It's useful clinical and operational knowledge — and understanding why those specific medicines are on the list (supply issues, price spikes, licensing changes) tells you something about how medicines markets actually work.
The MP's comment about being "addicted to low-cost drugs" suggests this is reaching political attention. That doesn't automatically mean action, but it does mean the conversation is moving beyond professional bodies and into Parliament. Whether that produces meaningful policy change or just rhetoric is the question.
For the profession, the pressure is real and it isn't easing. Four consecutive record months of concessions is the data. CPE's call for fundamental reform is the response. What comes next depends on whether NHS England and government treat this as an urgent structural problem or continue to manage it month by month.
Source: Chemist+Druggist — https://www.chemistanddruggist.co.uk/news/politics/worsening-price-concessions-hit-yet-another-record-high-FEQUCGSCIRDDDNW2BH2GRSYP3I/